Gene · 634
Papers3,222
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,222
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression. | PLoS Pathog | 2023 | 37410700 | PubTator, text mining | PubMed |
| Classification and characterisation of extracellular vesicles-related tuberculosis subgroups and immune cell profiles. | J Cell Mol Med | 2023 | 37409682 | PubTator, text mining | PubMed |
| Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas. | Biomark Res | 2023 | 37403120 | PubTator, text mining | PubMed |
| [Functional diversity of disorder-specific macrophage subtype]. | Nihon Yakurigaku Zasshi | 2023 | 37394548 | PubTator, text mining | PubMed |
| Identification of the shared gene signatures and molecular pathways in systemic lupus erythematosus and diffuse large B-cell lymphoma. | J Gene Med | 2023 | 37392050 | PubTator, text mining | PubMed |
| Appearance of tuft cells during prostate cancer progression. | Oncogene | 2023 | 37386128 | PubTator, text mining | PubMed |
| A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer. | Front Endocrinol (Lausanne) | 2023 | 37383389 | PubTator, text mining | PubMed |
| Vertebrate and Invertebrate Animal and New In Vitro Models for Studying Neisseria Biology. | Pathogens | 2023 | 37375472 | PubTator, text mining | PubMed |
| The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice. | Front Pharmacol | 2023 | 37361202 | PubTator, text mining | PubMed |
| Prognostic prediction and immunotherapy response analysis of the fatty acid metabolism-related genes in clear cell renal cell carcinoma. | Heliyon | 2023 | 37360096 | PubTator, text mining | PubMed |
| Traditional Chinese medicine Kuan-Sin-Yin decoction inhibits cell mobility via downregulation of CCL2, CEACAM1 and PIK3R3 in hepatocellular carcinoma cells. | J Ethnopharmacol | 2023 | 37355084 | PubTator, text mining | PubMed |
| The landscape of abnormal pathway activation confers COVID-19 patients' molecular sequelae earlier than clinical phenotype. | Theranostics | 2023 | 37351167 | PubTator, text mining | PubMed |
| Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints. | Cancers (Basel) | 2023 | 37345111 | PubTator, text mining | PubMed |
| Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. | Cancers (Basel) | 2023 | 37345057 | PubTator, text mining | PubMed |
| Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. | Cancers (Basel) | 2023 | 37345056 | PubTator, text mining | PubMed |
| DIS3L2 knockdown impairs key oncogenic properties of colorectal cancer cells via the mTOR signaling pathway. | Cell Mol Life Sci | 2023 | 37340282 | PubTator, text mining | PubMed |
| Optimized cell type signatures revealed from single-cell data by combining principal feature analysis, mutual information, and machine learning. | Comput Struct Biotechnol J | 2023 | 37333862 | PubTator, text mining | PubMed |
| New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). | Int J Oncol | 2023 | 37326100 | PubTator, text mining | PubMed |
| Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies. | Essays Biochem | 2023 | 37313600 | PubTator, text mining | PubMed |
| Changes in the expression of cancer- and metastasis-related genes and proteins after metformin treatment under different metabolic conditions in endometrial cancer cells. | Heliyon | 2023 | 37313172 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/634/papers?page=18